(PRWEB) July 02, 2012
The US Drug Watchdog is saying, "We want to make certain every woman in the United States who used the osteoporosis drug called Fosamax and then suffered an out of the blue femur break gets identified, and we want to make certain they get to the best possible personal injury attorneys, so they get the maximum possible compensation for what they have been through. Most women victims we have spoken with describe the experience as the post painful of their lives." These type of leg breaks are also called atypical fractures. On February 3rd 2011, The Journal of the American Medical Association (JAMA) came out with a Canadian medical study that points to a higher risk of a certain type of femur, or thighbone fractures in women, who take bisphosphonates such as Fosamax for long periods of time. This type of fracture can happen suddenly and without warning, so based on the JAMA study, this could be a particularly serious side effect of the osteoporosis drug called Fosamax. The US Drug Watchdog wants to hear from any woman, who was using the osteoporosis drug Fosamax for five years, or more, and then suffered an unexplained femur break, also known as a thighbone break. For more information please contact the US Drug Watchdog at 866-714-6466, or contact the group via their web site at http://USDrugWatchdog.Com
The US Drug Watchdog is the premier private pharmaceutical watchdog, and advocacy group in the United States. The group says, "Most importantly we want to get the word out about Fosamax, and to long term users, who have suffered from an unexplainable broken femur or broken leg. At the same time, we want to make certain all Fosamax users who suffered an unexplained broken femur or thigh bone get to the actual trial law firms or attorneys that have the best record in achieving superior results for their clients-period." For more information please contact the US Drug Watchdog anytime at 866-714-6466, or contact the group via its web site at http://USDrugWatchdog.Com
MDL No. 2243-In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II)
Read the full story at http://www.prweb.com/releases/2012/7/prweb9654153.htm.
Copyright©2012 Vocus, Inc.
All rights reserved